CA3215685A1 - Transdermal pharmaceutical formulations for the treatment of chronic pain - Google Patents
Transdermal pharmaceutical formulations for the treatment of chronic pain Download PDFInfo
- Publication number
- CA3215685A1 CA3215685A1 CA3215685A CA3215685A CA3215685A1 CA 3215685 A1 CA3215685 A1 CA 3215685A1 CA 3215685 A CA3215685 A CA 3215685A CA 3215685 A CA3215685 A CA 3215685A CA 3215685 A1 CA3215685 A1 CA 3215685A1
- Authority
- CA
- Canada
- Prior art keywords
- transdermal
- pain
- once
- pharmaceutical composition
- patch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163177981P | 2021-04-22 | 2021-04-22 | |
| US63/177,981 | 2021-04-22 | ||
| PCT/IB2022/053730 WO2022224184A1 (en) | 2021-04-22 | 2022-04-21 | Transdermal pharmaceutical formulations for the treatment of chronic pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3215685A1 true CA3215685A1 (en) | 2022-10-27 |
Family
ID=83722736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3215685A Pending CA3215685A1 (en) | 2021-04-22 | 2022-04-21 | Transdermal pharmaceutical formulations for the treatment of chronic pain |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220347151A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4326252A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024514362A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117545478A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022260813A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3215685A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023012483A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022224184A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12186280B2 (en) | 2019-10-11 | 2025-01-07 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| CN119896633A (zh) * | 2025-01-17 | 2025-04-29 | 中国人民解放军空军军医大学 | 一种水凝胶冷敷贴及其制备的冷热敷贴套装和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR19990026792A (ko) * | 1997-09-26 | 1999-04-15 | 김윤 | 디클로페낙 디에틸암모늄염을 함유한 매트릭스형 패취제제 |
| WO2010127033A1 (en) * | 2009-04-28 | 2010-11-04 | Alltranz Inc. | Formulations of cannabidiol and methods of using the same |
| PT2473475T (pt) * | 2009-08-31 | 2017-08-02 | Zynerba Pharmaceuticals Inc | Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas |
| US20160022627A2 (en) * | 2014-04-18 | 2016-01-28 | Mary's Medicinals LLC | Transdermal cannabinoid patch |
| US10272125B2 (en) * | 2015-09-14 | 2019-04-30 | Life Tech Global, Llc | Transdermal delivery of cannabidiol with other active moieties including cannabinoids |
| MX2018004034A (es) * | 2015-09-30 | 2018-12-19 | Edward Hoag George | Formulaciones topicas de analgesicos para alivio del dolor fabricacion y uso de los mismos. |
| US10525093B2 (en) * | 2016-11-14 | 2020-01-07 | Farm To Farma, Inc. | Cannabinoid formulations and method of making the same |
| US10966946B2 (en) * | 2016-11-17 | 2021-04-06 | Cmpd Licensing, Llc | Compounded compositions and methods for treating pain |
| IL292126B2 (en) * | 2018-01-12 | 2025-04-01 | Nutrae Llc | Cannabinoid formulations are formulated for oral administration |
| CA3060926A1 (en) * | 2018-09-06 | 2020-03-06 | NuVessl, Inc. | Method of using cannabinoids encapsulated in phospholipid carriers for transmucosal and transdermal administration |
| US20200197359A1 (en) * | 2018-09-17 | 2020-06-25 | Cody D. Freeze | Cannabinoid and Terpene-Infused Topical Cream |
| CN118831076A (zh) * | 2019-03-12 | 2024-10-25 | Epm (Ip)公司 | 大麻素酸酯组合物及其用途 |
| AU2020301119B2 (en) * | 2019-06-28 | 2026-03-05 | Nexzol Pharma, Inc. | Transdermal formulations |
| CN114650809A (zh) * | 2019-10-03 | 2022-06-21 | 斯塔顿治疗公司 | 屈大麻酚的透皮递送 |
| US12016829B2 (en) * | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| US12186280B2 (en) * | 2019-10-11 | 2025-01-07 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| US12121617B2 (en) * | 2019-10-14 | 2024-10-22 | Pike Therapeutics Inc. | Transdermal delivery of cannabidiol |
| JP2022551730A (ja) * | 2019-10-14 | 2022-12-13 | パイク セラピューティクス,インコーポレイテッド | カンナビジオールの経皮送達 |
| US20210346310A1 (en) * | 2020-04-20 | 2021-11-11 | Pike Therapeutics, Inc. | Transdermal and/or topical, pharmaceutical formulations comprising cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain |
| WO2022003623A1 (en) * | 2020-07-01 | 2022-01-06 | Pike Therapeutics, Inc. | Transdermal pharmaceutical formulations for the treatment of multiple sclerosis |
| US20220047541A1 (en) * | 2020-08-17 | 2022-02-17 | Pike Therapeutics, Inc. | Pharmaceutical compositions and methods for treating parkinson's disease |
| MX2023006561A (es) * | 2020-12-03 | 2023-07-06 | Pike Therapeutics Inc | Formulaciones farmaceuticas transdermicas que comprenden cbd o thc para el tratamiento del cancer. |
-
2022
- 2022-04-21 AU AU2022260813A patent/AU2022260813A1/en not_active Abandoned
- 2022-04-21 JP JP2023564654A patent/JP2024514362A/ja active Pending
- 2022-04-21 CN CN202280044571.8A patent/CN117545478A/zh active Pending
- 2022-04-21 US US17/725,593 patent/US20220347151A1/en not_active Abandoned
- 2022-04-21 CA CA3215685A patent/CA3215685A1/en active Pending
- 2022-04-21 WO PCT/IB2022/053730 patent/WO2022224184A1/en not_active Ceased
- 2022-04-21 EP EP22791231.8A patent/EP4326252A4/en not_active Withdrawn
- 2022-04-21 MX MX2023012483A patent/MX2023012483A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN117545478A (zh) | 2024-02-09 |
| US20220347151A1 (en) | 2022-11-03 |
| EP4326252A1 (en) | 2024-02-28 |
| MX2023012483A (es) | 2023-11-03 |
| WO2022224184A1 (en) | 2022-10-27 |
| JP2024514362A (ja) | 2024-04-01 |
| EP4326252A4 (en) | 2025-03-12 |
| AU2022260813A1 (en) | 2023-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250248948A1 (en) | Transdermal and/or Topical, Pharmaceutical Formulations Comprising Cannabidiol and/or Tetrahydrocannabinol for the Treatment of Chronic Pain | |
| CA3187588A1 (en) | Transdermal pharmaceutical formulations of cannabinoids | |
| US20260076921A1 (en) | Transdermal Pharmaceutical Formulations for the Treatment of Multiple Sclerosis | |
| AU2020361741B2 (en) | Transdermal compositions comprising cannabidiol (CBD) for use in the treatment of seizure disorders | |
| CN114555068A (zh) | 大麻二酚的透皮给药 | |
| US12121617B2 (en) | Transdermal delivery of cannabidiol | |
| JP2022550569A (ja) | ドロナビノールの経皮送達 | |
| WO2022224184A1 (en) | Transdermal pharmaceutical formulations for the treatment of chronic pain | |
| US20240261235A1 (en) | Pharmaceutical Composition And Method For Treating Seizure Disorders | |
| CA3213953A1 (en) | Pharmaceutical composition and method for treating seizure disorders | |
| US20250049821A1 (en) | Pharmaceutical Composition and Method for Treating Seizure Disorders | |
| CA3214228A1 (en) | Transdermal delivery of cannabidiol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - SMALL Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250411 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250411 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260602 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260625 |